Inhibition of calcium-activated neutral protease, in muscle and nerve, by the tripeptide leupeptin after median nerve transection and epineural repair in monkeys (Cebus apella) was studied. Results indicate that inhibition of the protease after nerve repair facilitates morphologic recovery in denervated thenar muscles and in distal thenar nerve branches. In additiok, functional recovery was facilitated in leupeptin-treated animals after nerve repair as measured by sensory and motor conduction velocities. Toxicologic testing showed that leupeptin, administered at 18 mg/kg, intramuscularly, twice daily, for 6 months did not adversely affect hematology, clotting, or plasma complement component C3 profiles. These data indicate that leupeptin is an effective and safe adjunct to peripheral nerve repair.
cytochemically localized in normal primate muscle and normal primate peripheral nerve. In vivo administration of the thiolprotease inhibitor leupeptin abolished the immunoreactivity in muscle and peripheral nerve (18) . These data suggested that binding of leupeptin to CANP prevented the interaction with anti-CANP antibody, presumably at the active site, and further demonstrated the accessibility of intracellular CANP to injected leupeptin. These data and our previous studies (13) (14) (15) (16) ) further strengthened our hypothesis that inhibition of muscle and neural CANP with leupeptin subsequent to peripheral nerve repair might facilitate neuromuscular recovery.
This study was undertaken to test this hypothesis in a primate median nerve model (Cebus apella), which closely approximated anatomic and regenerative aspects of the human. Excellent functional results after peripheral nerve repair in humans still cannot be consistently obtained or reliably predicted (19, 20) . Therefore, adjunctive methods to nerve repair that facilitate neuromuscular recovery may provide useful therapies in humans.
MATERIALS AND METHODS
Neuromicrosurgery and Treatment. Ten young adult Capuchin monkeys (C. apella) (3-4 kg) were preanesthetized with ketamine and atropine, intubated tracheally, and maintained on halothane anesthesia with cardiac monitoring. By using sterile technique and an operative microscope, all animals underwent a right median nerve transection, using nerve-holding forceps (Accurate Instruments, Westbury, NY) and a sharp 35-mm nerve blade, 1.5 cm proximal to the distal wrist crease. Both proximal and distal nerve stumps in five treated animals were immediately bathed and the right thenar muscles were injected with leupeptin at 18 mg/kg, dissolved in sterile 0.9% NaCi (0.25 ml, total volume). In the remaining five control animals, the transected proximal and distal nerve stumps were bathed in 0.25 ml of sterile O.9o NaCl only. Subsequently, all animals underwent an immediate epineural repair oftheir median nerves using 10-0 nylon, a 70-gm needle, and an average maximum of four circumferential suture points. To ensure that the animals did not rupture their nerve repairs, fiberglass long arm casts were applied for 4 weeks to hold the wrists in volar flexion and the elbow at 450-500 of flexion.
Beginning on post-operative day 1 and continuing for 6 months, treated animals received intramuscular injections in the hind limbs of leupeptin at 18 mg/kg in sterile 0.9% NaCl, twice daily, with 7 hr between the injections. Control animals were not injected since it was determined in a large group of rats (16) and a separate smaller group of Cebus monkeys (13) that control injections of saline only had no effects on neuromuscular recovery after nerve repair.
Conduction Velocities. At 6 and 8 weeks after nerve repair, all animals were anesthetized with ketamine and atropine and sensory and motor nerve conduction velocities were tested across the repair site. Similar conduction velocity tests were also performed on the (unoperated) left median nerves in all animals.
Muscle and Nerve Biopsy. At 3 months after nerve repair, animals were anesthetized as before and, by using a 3.5 x loupe, the nerve repair site was re-explored to assure that it was intact and free of neuroma. All animals underwent the following procedures: (i) months in the left (unoperated) hand of leupeptin-treated animals were somewhat larger, showed normal structure, and had a diameter of 46.2 ± 3.6 ,&m (mean ± SD). The difference between the mean values was statistically significant (P = 0.025).
The opponens pollicis myofibers biopsied at 3 months in the right (nerve-repaired) hand of control animals showed histological and ultrastructural features consistent with denervation, including persistent myofiber angulation, large round myofibers, central nuclei, and increased fibrosis (Fig.  1A) . These myofibers had a diameter of 22.27 ± 2.68 ,um (mean ± SD). In contrast, the nerve-repaired right opponens myofibers in treated animals were larger and averaged 37.60 ± 3.87 Aum in diameter (mean ± SD). These myofibers generally retained their typical polygonal shape with minimal denervation changes (Fig. 1B) . The mean difference in diameters was significant (P = 0).
At 6 months, abductor pollicis myofibers demonstrated similar results. The left control myofiber diameter was 40.57 ± 3.72 ,m (mean ± SD), and left treated myofibers were larger with a diameter of 45.72 ± 2.29 ,um (mean ± SD). This difference was statistically significant (P = 0.03). The denervated abductor pollicis myofibers in the right (nerverepaired) hand showed a striking difference in diameter between controls (28.25 ± 0.71 ,m) and treated (43.65 ± 5.30 ,m) animals (mean ± SD; P = 0).
Muscle Immunocytochemistry. Light and electron microscopic immunocytochemistry for CANP in left opponens and left abductor myofibers of control animals revealed the enzyme was associated with endomysial collagen fibrils, the myofiber basal lamina, sarcolemma, and Z-bands, as we have reported (18) (Fig. 2A) . CANP was not detected in the left opponens and left abductor myofibers of leupeptin-treated animals (Fig. 2B) .
Immunocytochemistry of the denervated opponens and abductor in the right (nerve-repaired) hand of control animals showed that CANP was widely dispersed within myofibers (Fig. 3) . CANP was not detected in denervated opponens and abductor myofibers in the right (nerve-repaired) hand of leupeptin-treated animals (Fig. 4) . In all muscle sections incubated in adsorbed antibody, CANP was not detected.
Nerve Morphology. As a morphologic indicator of axon regrowth, axons were counted 3.0 cm distal to the nerve repair on the right median nerve branch to the opponens (3 months) and the right branch to the abductor (6 months). Axons were also counted in the left nerves at the corresponding anatomic location of all animals to establish normal values. Ten randomly selected light microscopic and 10 randomly selected electron microscopic section fields per nerve were quantitated. Constant magnification of fields was used for light and electron microscopy.
The mean number of axons was consistently higher and statistically significant in the right leupeptin-treated nerves compared to the right control nerves at both biopsy intervals. The only exception to this was the number of unmyelinated axons at 6 months in the abductor branch where there was no statistical significance between treated and control animals. The effects of treatment on axon numbers in the left (unoperated) hand of all animals were not significant. Figs. 5 and 6 summarize these data.
As an additional morphologic indicator of distal axon regrowth, mean thickness of the myelin sheath was measured   FIG. 4 In contrast, in the right opponens and abductor nerve branches, myelin sheath thickness was affected by leupeptin treatment. At 3 months, in the right opponens nerve, the thickness was 0.15 ± 0.14 ,m in controls but was significantly increased to 0.51 ± 0.17 ,m in treated animals (mean Nerve Immunocytochemistry. Light and electron microscopic immunocytochemistry on control opponens and abductor nerves in the left (unoperated) hand revealed CANP to be associated with endoneurial collagen fibrils, basal lamina of Schwann cells of myelinated and unmyelinated axons, axolemma, and neurofilaments of both axon types. CANP was not detected in left opponens and abductor nerves of leupeptin-treated animals and in sections of nerve incubated in adsorbed antibody, which is consistent with our previous study (18) .
In denervated opponens and abductor nerves of control animals, CANP was detected in myelinated and unmyelinated axons in association with basal lamina, axolemma, and neurofilaments and was most pronounced 3 months after nerve repair. In the denervated opponens and abductor nerves of leupeptin-treated animals, CANP was not detected after nerve repair.
Nerve Conduction Velocities. At 6 and 8 weeks after nerve repair, leupeptin-treated animals showed faster motor and sensory conduction velocities across the repair site when compared to control animals. These results are summarized in Figs. 7 
DISCUSSION
Our results using a primate median nerve model suggest that the tripeptide leupeptin partially inhibits muscle denervation atrophy and enhances axon regrowth after immediate epineural nerve repair. This was demonstrated morphologically in treated animals by increased myofiber diameters with retention of normal myofiber morphology, increased numbers of myelinated and unmyelinated axons distal to the repair, and in increased myelin sheath thickness of distal axons.
The mechanism of leupeptin action in denervated muscle and nerve appears to be the direct inhibition ofCANP in these tissues. The anti-CANP antibody used in this study completely abolished CANP protease activity, suggesting that anti-CANP and leupeptin bind to a similar site on CANP. This would explain the lack of immunoreactivity against anti-CANP in muscle and nerve of leupeptin-treated animals. Our previous study in normal tissue (18) and present immunocytochemical results indicate that the site of CANP in normal muscle are the Z-band, sarcolemma, and basal lamina. After denervation, nerve repair, and leupeptin treatment, it appears that the disassembly of the myofiber is prevented by inhibition of CANP at these sites. Thus, we suggest that the myofiber basal lamina and end-target muscle are retained. These structures are known to be positive neurotrophic reinnervation targets (22) (23) (24) . In normal primate nerve, the basal lamina, axolemma, and neurofilaments show immunoreactivity for CANP (18) . After denervation, nerve repair, and treatment, leupeptin inhibited CANP associated with these structures. We suggest that the enhanced axon regrowth observed after repair and CANP inhibition by leupeptin may relate to retention of the axonal basal lamina in distal nerve segments. Leupeptin treatment may preserve this structure known to be a regenerative substrate for axonal adherence and elongation (25, 26) .
The ultimate determination of efficacy of any adjunctive treatment for peripheral nerve repair will of course relate to subsequent functional recovery. In this study, motor and sensory conduction were positively affected by leupeptin treatment. This was shown by faster nerve conduction velocity values in treated animals when compared to controls. These findings appear to correlate with the positive morphologic observations after treatment. Increased numbers of distal axons, especially myelinated axons possessing thicker myelin sheaths, are known to conduct more rapid depolarization impulses (27) .
Finally, the dose, frequency, and method of administration of leupeptin used in this study were based on prior serum absorption studies in monkeys (13) , indicating that the tripeptide is rapidly absorbed in serum 1 hr after intramuscular administration with a linear decline by 24 hr to only trace amounts. We have also noted (13) that a single intramuscular dose of 24 mg/kg negatively affected clotting profiles, presumably by the leupeptin inhibition of thrombokinase (28) . Therefore, our use of 18 mg/kg, twice daily, was designed to ensure that serum levels of 2-4 ,ug/ml were consistently maintained. This treatment did not affect normal hematology, clotting, or C3 values.
With regard to C3 values, it appears that our twice-daily intramuscular leupeptin injections did not initiate formation of adverse antigen-antibody (immune) plasma complexes. These complexes may bind complement in a number of host tissue compartments, release C3, and ultimately cause hydrolytic enzyme destruction of tissues. Since no difference in C3 values was noted between leupeptin-treated and control animals, formation of immune plasma complexes does not appear to occur after leupeptin treatment.
This study indicates that leupeptin is a potentially significant and safe adjunct to the microsurgical repair of peripheral nerves and warrants human clinical testing.
